Jefferies initiates buy on Krystal Biotech with a $245 price target, citing Vyjuvek's strong growth potential and proprietary ...

Fintel reports that on March 5, 2025, Jefferies initiated coverage of Krystal Biotech (NasdaqGS:KRYS) with a Buy ...

Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

According to Benzinga Pro, Krystal Biotech's peer group average for short interest as a percentage of float is 12.98%, which ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

Investors might want to bet on Krystal Biotech, Inc. (KRYS), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price ...

Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been given an average recommendation of “Buy” by the ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) rose 7.1% during mid-day trading on Thursday after Citigroup raised their price target on the stock from $206.00 to $215.00. Citigroup ...

Would you like to be notified of the latest news and updates on the stock market?

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...